Enanta Pharmaceuticals, Inc. (ENTA)
NASDAQ: ENTA · Real-Time Price · USD
16.85
+0.25 (1.51%)
At close: Dec 26, 2025, 4:00 PM EST
16.51
-0.34 (-2.02%)
After-hours: Dec 26, 2025, 6:43 PM EST
Enanta Pharmaceuticals Revenue
In the fiscal year ending September 30, 2025, Enanta Pharmaceuticals had annual revenue of $65.32M, down -3.42%. Enanta Pharmaceuticals had revenue of $15.13M in the quarter ending September 30, 2025, with 3.55% growth.
Revenue (ttm)
$65.32M
Revenue Growth
-3.42%
P/S Ratio
5.50
Revenue / Employee
$544,367
Employees
120
Market Cap
486.33M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Sep 30, 2025 | 65.32M | -2.31M | -3.42% |
| Sep 30, 2024 | 67.64M | -11.57M | -14.61% |
| Sep 30, 2023 | 79.20M | -6.96M | -8.07% |
| Sep 30, 2022 | 86.16M | -10.91M | -11.24% |
| Sep 30, 2021 | 97.07M | -25.40M | -20.74% |
| Sep 30, 2020 | 122.47M | -82.72M | -40.31% |
| Sep 30, 2019 | 205.20M | -1.43M | -0.69% |
| Sep 30, 2018 | 206.63M | 103.81M | 100.97% |
| Sep 30, 2017 | 102.81M | 14.55M | 16.48% |
| Sep 30, 2016 | 88.27M | -72.61M | -45.13% |
| Sep 30, 2015 | 160.88M | 113.14M | 236.98% |
| Sep 30, 2014 | 47.74M | 15.69M | 48.94% |
| Sep 30, 2013 | 32.05M | -9.65M | -23.15% |
| Sep 30, 2012 | 41.71M | -176.00K | -0.42% |
| Sep 30, 2011 | 41.88M | 19.12M | 83.99% |
| Sep 30, 2010 | 22.76M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 435.16B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 64.24B |
| AbbVie | 59.64B |
| Eli Lilly and Company | 59.42B |
| AstraZeneca | 58.13B |
| Novartis AG | 56.37B |
| Novo Nordisk | 49.58B |
ENTA News
- 5 weeks ago - Enanta: Maintaining Buy Rating Based On Zelicapavir Potential In RSV Development - Seeking Alpha
- 5 weeks ago - Enanta Pharmaceuticals Reports Financial Results for its Fiscal Fourth Quarter and Year-Ended September 30, 2025 - Business Wire
- 7 weeks ago - Enanta Pharmaceuticals to Participate in Upcoming Investor Conferences - Business Wire
- 2 months ago - Enanta Pharmaceuticals Presents New Data for Zelicapavir, its N-Protein Inhibitor, and EDP-323, its L-Protein Inhibitor, Both in Development for the Treatment of Respiratory Syncytial Virus (RSV) at IDWeek™ 2025 - Business Wire
- 2 months ago - Enanta Pharmaceuticals to Present Data for Zelicapavir and EDP-323, Two Candidates in Development for the Treatment of Respiratory Syncytial Virus (RSV) at IDWeek™ 2025 - Business Wire
- 3 months ago - Enanta Pharmaceuticals Announces Closing of Upsized Public Offering of Common Stock, Including Full Exercise of Underwriters' Option to Purchase Additional Shares - Business Wire
- 3 months ago - Cal-Maine Foods Posts Downbeat Earnings, Joins Enanta Pharmaceuticals, AAR And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session - Benzinga
- 3 months ago - Enanta Pharmaceuticals Announces Pricing of Upsized Public Offering of Common Stock - Business Wire